Basilea Pharmaceutica Lifts FY26 Guidance

MT Newswires · 2d ago
02:43 AM EDT, 10/27/2026 (MT Newswires) -- Basilea Pharmaceutica (BSLN.SW) on Tuesday raised its full-year 2026 outlook. The Swiss-listed biopharmaceutical company now expects a 123% jump in its 2026 operating profit to 115 million francs from 51.5 million francs a year ago. The previous guidance was for a 40% increase The company forecasts its revenue to increase 33% to 310 million francs from 232.4 million francs a year earlier. Previously, it projected a 15% increase in revenue.